Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

mg twice daily, steady-state mean trough concentrations ranged from approximately 150 -- 300 ng/ml, which are well above the EC50 (concentration required for 50% inhibition of viral replication) of RDEA806 (EC50 = 1.67 ng/ml).

Evaluation of the drug-drug interaction liability, in vitro and in vivo, demonstrated that RDEA806 is unlikely to be an inducer or inhibitor of major P450 enzymes or be affected by CYP3A4 inhibitors. When given together with ritonavir, an HIV protease inhibitor and potent inhibitor of CYP3A4, plasma levels of RDEA806 were not significantly altered. These data support preclinical data that RDEA806 may have a reduced potential for drug-drug interactions, which could ultimately lead to a safer and more convenient treatment option for patients and physicians.

"We recognize the need for new HIV drugs that demonstrate potent antiviral activity against a wide range of viral isolates, including those that are resistant to currently available NNRTIs, and that show improved safety, tolerability and reduced potential for drug-drug interactions. Yesterday's presentation of the broad spectrum of antiviral activity of RDEA806 demonstrated its in vitro activity against the majority of HIV strains carrying key reverse transcriptase mutations, including coverage of the 10 most prevalent strains of HIV found in patients failing therapy with efavirenz, marketed as Sustiva(R) by Bristol-Myers Squibb*. Based on this very favorable preclinical profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2a proof-of-concept study in HIV-infected patients, which we plan to initiate before the end of this year. The terminal half-life of up to 13 hours also gives us the opportunity to evaluate once-daily dosing in Phase 2a," said Barry D. Quart, PharmD, President and CEO.

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... EGFR mutation   is a viable alternative to tumour biopsy ... testing in all patients with advanced NSCLC   ... effectiveness of plasma circulating tumour DNA (ctDNA) testing for epidermal ... with advanced non-small cell lung cancer (NSCLC) in clinical practice. ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/5hkm2f/medical_oxygen ) has announced ... Global Strategic Business Report" report to their offering. ... Medical Oxygen Systems in US$ Thousands by the following ... Regulators, and Oxygen Conserving Devices. The report provides separate ... , Japan , Europe ...
(Date:4/17/2015)... DUBLIN , Apr. 16, 2015 Research and ... addition of the "Corporate Reputation of Pharma in ... 2nd edition" report to their offering. ... perspectives from 130 patient groups with an interest in ... companies (and of the pharma industry as a whole) ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Medical Oxygen Systems - 2015 Global Strategic Business Report Featuring Leading Players, Caire, Invacare & Philips Respironics 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 2Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 3Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 4Perspective of Diabetes Patient Groups on the Corporate Reputation of Pharma in 2014: 130 patient groups with an interest in diabetes from 34 countries 5
... MELVILLE, N.Y., April 23, 2012  Henry Schein, ... provider of health care products and services to dental, ... with the launch of its 2012 Global Reflections program ... "Henry Schein firmly believes that protecting ...
... Systems, Inc. (NASDAQ: DCTH ) today announced it ... revolver with Silicon Valley Bank ("SVB"), a leading provider of ... available for general corporate purposes supporting the overall growth and ... transaction, Eamonn P. Hobbs, President & CEO of Delcath Systems, ...
Cached Medicine Technology:Henry Schein Celebrates Earth Day 2Henry Schein Celebrates Earth Day 3Delcath Systems, Inc. Secures $20 Million Credit Facility 2Delcath Systems, Inc. Secures $20 Million Credit Facility 3Delcath Systems, Inc. Secures $20 Million Credit Facility 4
(Date:4/18/2015)... 18, 2015 More than 2000 styles ... at TheCelebrityDresses.com, the #1 online store carrying celebrity inspired ... girls have got their perfect dresses for their prom. ... fashion prom dresses at TheCelebrityDresses.com would be an ideal ... than 2000 prom dresses inspired by the most loved ...
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Therapy Association Annual Conference to be held May ... SC. , The SCAPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... 18, 2015 PHOENIX, ARIZONA – In ... with 11 other secure destruction professionals across the United ... (CSDS). He will now display “CSDS” as a professional ... before the National Association of Information Destruction 2015 Annual ... Grapevine, Texas. Of the 20 people who took the ...
(Date:4/17/2015)... (PRWEB) April 18, 2015 Heritage Woods ... begin its Supportive Living Week Celebration on April 20 ... having a healthy mind, body and soul. , The ... McLeansboro, Illinois, serves older adults of all incomes, including ... their independence. , Supportive Living Week is observed every ...
(Date:4/17/2015)... NY (PRWEB) April 18, 2015 Rosetta ... their facility, rounding out their list of diagnostic imaging ... center for patients on the Upper East Side of ... running at full capacity. The addition of PET-CT, combined ... their physicians the ability to work with patients through ...
Breaking Medicine News(10 mins):Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3
... By Amanda Gardner HealthDay Reporter , MONDAY, ... pediatricians is calling for a ban on all junk food ... means of slowing the rising tide of obesity among young ... issue of Pediatrics , the American Academy of Pediatrics ...
... This release is available in German . ... more than one million euros in research and development funding ... at the research neutron source FRM II. In a 2009 ... the high neutron flux the neutron source in Garching can ...
... Hughes Medical Institute, the Max Planck Society and the ... a new, top-tier, open access journal for biomedical and ... establish a new journal that will attract and define ... All research published in the journal will make highly ...
... HealthDay Reporter , SUNDAY, June 26 (HealthDay News) -- ... lose weight, and low-fat diets that are either high in ... researchers say. "I think there are two key messages ... a senior lecturer with the school of medicine and health ...
... illicit drug used by teenagers and adults around the world. ... States report smoking it, and most high schoolers say they ... smoking pot is no big deal. They cite reasons such ... it." Denise Walker, co-director of the University of Washington,s ...
... tested a predatory bacterium Bdellovibrio against ... found that it significantly reduced the numbers of Salmonella ... safe when ingested. The research was funded by ... Professor Liz Sockett,s team at The University of Nottingham, with ...
Cached Medicine News:Health News:Doctors Urge Ban on Junk Food Ads During Kids' Shows 2Health News:Doctors Urge Ban on Junk Food Ads During Kids' Shows 3Health News:Cancer diagnosis isotopes from Garching 2Health News:Leading research organizations announce top-tier journal for biomedical and life sciences 2Health News:Calories, Not Protein or Carbs, Are Key to Weight Loss: Study 2Health News:Calories, Not Protein or Carbs, Are Key to Weight Loss: Study 3Health News:2 talks with teens leads to less marijuana use for at least a year 2Health News:2 talks with teens leads to less marijuana use for at least a year 3Health News:Living antibiotic effective against Salmonella 2
... comfortable lightweight brace is designed for ... ulnar fractures. The anatomically correct design ... compression for optimal control of ulnar ... elbow motion is permitted to prevent ...
... Blue Line Wrist Control offers a custom ... support for Carpal Tunnel Syndrome, tendinitis, sprains, ... wrist. Careful design leaves fingers free for ... Lightweight metal stay can be contoured for ...
... The RCAI Dorsal Blocking Splint is constructed of ... The DBS protects the flexor tendons of the ... prevents scar tissue development in the later stages ... rest dorsally on the hand and positions the ...
Used for fractures of the phalanges where extension is required. Used to immobilize the joint following dislocation. Curved to conform to the finger.Choose from four sizes 1.5", 2.5", 4" and 6". Unpa...
Medicine Products: